Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 23;321(16):1627-1629.
doi: 10.1001/jama.2019.2990.

Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018

Inmaculada Hernandez  1 , Chester B Good  2 , William H Shrank  2   3 , Walid F Gellad  4
Affiliations

Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018

Inmaculada Hernandez et al. JAMA. .

Abstract

This study uses Medicaid drug utilization data to describe reimbursement and market share of long-acting insulins before and after approval of new insulin products and to estimate savings associated with a “biosimilar” for insulin glargine approved in 2015.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Mean Medicaid Reimbursement Rate and Market Share of Long-Acting Insulin Products, 2005-2018
The upper panel shows the mean reimbursement per 100 international units for each long-acting insulin product and quarter, before minimum statutory rebates, and expressed in nominal dollars. The lower panel shows the market share of each long-acting insulin product, which was defined as the proportion of international units for long-acting insulins reimbursed by Medicaid in each quarter for each insulin product. Lantus is insulin glargine; Basaglar, “biosimilar” for insulin glargine; Toujeo, highly concentrated insulin glargine; Levemir, insulin detemir; Tresiba, insulin degludec; and Soliqua, combination insulin glargine and lixisenatide.
See this image and copyright information in PMC

References

    1. Luo J, Avorn J, Kesselheim AS. Trends in Medicaid reimbursements for insulin from 1991 through 2014. JAMA Intern Med. 2015;175(10):1681-1686. doi:10.1001/jamainternmed.2015.4338 - DOI - PubMed
    1. Hua X, Carvalho N, Tew M, Huang ES, Herman WH, Clarke P. Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013. JAMA. 2016;315(13):1400-1402. doi:10.1001/jama.2016.0126 - DOI - PMC - PubMed
    1. Greene JA, Riggs KR. Why is there no generic insulin? historical origins of a modern problem. N Engl J Med. 2015;372(12):1171-1175. doi:10.1056/NEJMms1411398 - DOI - PubMed
    1. US Food and Drug Administration Center for Drug Evaluation and Research Approval package for Basaglar. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205692Orig1s000A.... Accessed January 7, 2019.
    1. Centers for Medicare & Medicaid Services Medicaid drug rebate program. https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebat.... Accessed September 25, 2018.

Publication types

MeSH terms